Published in Virology on October 10, 2004
Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor. J Infect Dis (2010) 2.00
A novel CCR5 mutation common in sooty mangabeys reveals SIVsmm infection of CCR5-null natural hosts and efficient alternative coreceptor use in vivo. PLoS Pathog (2010) 1.48
Naïve and memory cell turnover as drivers of CCR5-to-CXCR4 tropism switch in human immunodeficiency virus type 1: implications for therapy. J Virol (2006) 1.31
Frequent CXCR4 tropism of HIV-1 subtype A and CRF02_AG during late-stage disease--indication of an evolving epidemic in West Africa. Retrovirology (2010) 1.25
Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands. Virology (2007) 1.21
Long-lasting CCR5 internalization by antibodies in a subset of long-term nonprogressors: a possible protective effect against disease progression. Blood (2006) 1.03
CCR5: From Natural Resistance to a New Anti-HIV Strategy. Viruses (2010) 0.91
Persistence and emergence of X4 virus in HIV infection. Math Biosci Eng (2011) 0.83
Infection of macrophages and dendritic cells with primary R5-tropic human immunodeficiency virus type 1 inhibited by natural polyreactive anti-CCR5 antibodies purified from cervicovaginal secretions. Clin Vaccine Immunol (2008) 0.82
Dualtropic CXCR6/CCR5 Simian Immunodeficiency Virus (SIV) Infection of Sooty Mangabey Primary Lymphocytes: Distinct Coreceptor Use in Natural versus Pathogenic Hosts of SIV. J Virol (2015) 0.80
Accelerated immunodeficiency by anti-CCR5 treatment in HIV infection. PLoS Comput Biol (2009) 0.79
Natural anti-CCR5 antibodies in HIV-infection and -exposure. J Transl Med (2011) 0.79
A quantitative comparison of anti-HIV gene therapy delivered to hematopoietic stem cells versus CD4+ T cells. PLoS Comput Biol (2014) 0.78
HIV-1 Transmission, Replication Fitness and Disease Progression. Virology (Auckl) (2008) 0.78
Stochastic model of in-vivo X4 emergence during HIV infection: implications for the CCR5 inhibitor maraviroc. PLoS One (2012) 0.76
HIV vaccine design and the neutralizing antibody problem. Nat Immunol (2004) 9.48
The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J Virol (2002) 6.11
Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med (2003) 5.71
Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science (2013) 5.53
A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science (2011) 5.44
Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science (2004) 5.31
Inhibiting sexual transmission of HIV-1 infection. Nat Rev Microbiol (2003) 5.29
Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature (2005) 4.71
Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science (2013) 4.61
AIDS. Promote HIV chemoprophylaxis research, don't prevent it. Science (2005) 4.44
A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog (2013) 4.23
Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science (2004) 3.95
AIDS vaccine models: challenging challenge viruses. Nat Med (2002) 3.92
Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS One (2008) 3.85
Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol (2002) 3.59
Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med (2008) 3.35
HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci U S A (2002) 3.28
Acute loss of intestinal CD4+ T cells is not predictive of simian immunodeficiency virus virulence. J Immunol (2007) 3.24
Pathogenic simian immunodeficiency virus infection is associated with expansion of the enteric virome. Cell (2012) 3.22
Online submission makes authors do all the work. Nature (2005) 3.21
SIV(mac) pathogenesis in rhesus macaques of Chinese and Indian origin compared with primary HIV infections in humans. AIDS (2002) 3.19
Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat Struct Mol Biol (2013) 3.11
Biologic properties of mesenchymal stem cells derived from bone marrow and adipose tissue. J Cell Biochem (2006) 3.11
V3: HIV's switch-hitter. AIDS Res Hum Retroviruses (2005) 3.00
Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proc Natl Acad Sci U S A (2013) 2.96
Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J Virol (2009) 2.95
Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission. Annu Rev Med (2008) 2.81
Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. J Virol (2004) 2.80
Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLoS Pathog (2013) 2.66
Dynamic immune responses maintain cytotoxic T lymphocyte epitope mutations in transmitted simian immunodeficiency virus variants. Nat Immunol (2005) 2.60
Blockade of attachment and fusion receptors inhibits HIV-1 infection of human cervical tissue. J Exp Med (2004) 2.58
Comparing the ex vivo fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C. J Virol (2003) 2.52
Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate. J Virol (2002) 2.43
Paucity of CD4+CCR5+ T cells is a typical feature of natural SIV hosts. Blood (2006) 2.40
Viral escape from dominant simian immunodeficiency virus epitope-specific cytotoxic T lymphocytes in DNA-vaccinated rhesus monkeys. J Virol (2003) 2.39
Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc Natl Acad Sci U S A (2011) 2.39
Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures. Proc Natl Acad Sci U S A (2011) 2.38
Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection. J Exp Med (2003) 2.37
Whither or wither microbicides? Science (2008) 2.17
Simian-human immunodeficiency virus escape from cytotoxic T-lymphocyte recognition at a structurally constrained epitope. J Virol (2003) 2.15
Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239. J Virol (2003) 2.14
Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Virology (2005) 2.13
HIV-1 envelope triggers polyclonal Ig class switch recombination through a CD40-independent mechanism involving BAFF and C-type lectin receptors. J Immunol (2006) 2.12
11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J Exp Med (2005) 2.12
Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation. Proc Natl Acad Sci U S A (2013) 2.10
Genetic and functional analysis of full-length human immunodeficiency virus type 1 env genes derived from brain and blood of patients with AIDS. J Virol (2003) 2.07
Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein. J Virol (2002) 2.06
Simian immunodeficiency virus SIVagm.sab infection of Caribbean African green monkeys: a new model for the study of SIV pathogenesis in natural hosts. J Virol (2006) 2.05
Long-term in vitro expansion alters the biology of adult mesenchymal stem cells. Cancer Res (2008) 2.02
Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor. J Infect Dis (2010) 2.00
Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J Virol (2003) 1.97
HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology (2006) 1.97
Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins. J Virol (2002) 1.93
Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor. Nat Med (2005) 1.92
HIV-1 gp120 mannoses induce immunosuppressive responses from dendritic cells. PLoS Pathog (2007) 1.90
Structural and biological mimicry of protein surface recognition by alpha/beta-peptide foldamers. Proc Natl Acad Sci U S A (2009) 1.87
The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C. J Virol (2003) 1.86
Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody. J Infect Dis (2010) 1.79
Current concepts in AIDS pathogenesis: insights from the SIV/macaque model. Annu Rev Med (2007) 1.76
A macaque model of HIV-1 infection. Proc Natl Acad Sci U S A (2009) 1.76
Circulating human CD4 and CD8 T cells do not have large intracellular pools of CCR5. Blood (2010) 1.72
The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4. Virology (2004) 1.72
Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol (2005) 1.68
Molecular epidemiology of simian immunodeficiency virus SIVsm in U.S. primate centers unravels the origin of SIVmac and SIVstm. J Virol (2005) 1.66
Classic AIDS in a sooty mangabey after an 18-year natural infection. J Virol (2004) 1.66
Pathogenicity of simian-human immunodeficiency virus SHIV-89.6P and SIVmac is attenuated in cynomolgus macaques and associated with early T-lymphocyte responses. J Virol (2005) 1.63
HIV swiftly guts the immune system. Nat Med (2005) 1.61
Interaction of small molecule inhibitors of HIV-1 entry with CCR5. Virology (2006) 1.59